Precision BioSciences Says PBGENE-HBV Achieved Undetectable Viral RNA In 100% Of Evaluable Hepatitis B Patients At 0.4 mg/kg In Phase 1; Plans Phase 2 Dosing In Q1 2027
Share
Why It Matters
Precision BioSciences tested a new hepatitis B medicine on patients. All patients who got the right dose showed the virus disappeared, which is a very good early sign.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.